Cell Care Therapeutics is developing a new class of biologics that are derived from the secreted proteins and exosomes of mesenchymal stromal cells (MSCs). The company’s novel secretome platform harnesses the signaling molecules of MSCs to promote the health of blood vessels and their surrounding tissue. The company is developing its first product for the treatment of diabetic macular edema, the leading cause of vision loss in working age adults.